glp-1 and ibs Series Science-Irritable Bowel Syndrome GLP-1s and IBS: Genetic Insights

#type1diabetes #T1D #clinicaltrials To view or add a comment, sign in Featured Article: Bmal1 is a novel regulator and target for vascular calcification in diabetes, via a non-canonical circadian pathway mediated by Runx2 transcriptional activation To view or add a comment, sign in Featured Article: Bmal1 is a novel regulator and target for vascular calcification in diabetes, via a non-canonical circadian pathway mediated by Runx2 transcriptional activation To view or add a comment, sign in One Question [25]: Migraine headache medications Can you get the correct answer

Adding semaglutide or tirzepatide adds redundant GLP-1 (and GIP, in the case of tirzepatide) activity without new pathway coverage

,

When discussing testing, you can ask your provider about specific diagnostics used in environmental medicine

Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

The DAC version uses a drug affinity complex that extends half-life through albumin binding